(AMPH) Amphastar P - Ratings and Ratios

Amphastar Pharmaceuticals, Inc. is a bio-pharmaceutical company specializing in the development, manufacture, and sale of generic and proprietary injectable, inhalation, and intranasal products. The companys diverse product portfolio includes treatments for severe hypoglycemia, asthma, deep vein thrombosis, opioid overdose, and various other medical conditions. Amphastar Pharmaceuticals operates in the United States, China, and France, and has a strong presence in the pharmaceutical industry.

The companys product offerings include a range of injectable and inhalation products, such as BAQSIMI, Primatene Mist, Enoxaparin, REXTOVY, Naloxone, Glucagon, and Cortrosyn. Additionally, Amphastar Pharmaceuticals provides a variety of other products, including Amphadase, Epinephrine injection, Lidocaine jelly, and Phytonadione injection. The company is also involved in the development of generic product candidates and biosimilar product candidates, further expanding its presence in the pharmaceutical market.

From a technical analysis perspective, the stock has shown a recent price of $25.98, with a 20-day simple moving average (SMA) of $25.57 and a 50-day SMA of $24.76. The 200-day SMA is significantly higher at $36.28, indicating a potential long-term downtrend. The average true range (ATR) is 3.33%, suggesting moderate volatility. Given the current price is near the 52-week low of $22.99, a potential buying opportunity may arise if the stock can break through the resistance levels.

Fundamentally, Amphastar Pharmaceuticals has a market capitalization of $1.196 billion and a price-to-earnings (P/E) ratio of 9.20, indicating a relatively undervalued stock. The return on equity (RoE) is 19.37%, suggesting a strong profitability. With a forward P/E ratio not available, it is likely that the company is not expected to experience significant earnings growth in the near future.

Based on the technical and fundamental data, a forecast for Amphastar Pharmaceuticals can be made. If the stock can break through the resistance level of $26.50, it may continue to rise towards the 52-week high of $53.40. However, if the stock fails to break through this resistance, it may continue to consolidate around the current price. With a strong RoE and a relatively undervalued P/E ratio, the companys fundamentals are in place for potential long-term growth. Therefore, a potential buying opportunity may arise if the stock price dips towards the 52-week low, with a target price of $30-$35 in the next 6-12 months.